Corcept Therapeutics
Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CORT
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.
CORT Key Statistics
Stock Snapshot
As of today, Corcept Therapeutics(CORT) shares are valued at $35.50. The company's market cap stands at 3.78B, with a P/E ratio of 43.63.
On 2026-03-02, Corcept Therapeutics(CORT) stock traded between a low of $34.35 and a high of $35.50. Shares are currently priced at $35.50, which is +3.3% above the low and 0.0% below the high.
The Corcept Therapeutics(CORT)'s current trading volume is 354.62K, compared to an average daily volume of 2.63M.
In the last year, Corcept Therapeutics(CORT) shares hit a 52-week high of $117.33 and a 52-week low of $28.66.
In the last year, Corcept Therapeutics(CORT) shares hit a 52-week high of $117.33 and a 52-week low of $28.66.
CORT News
In February 2026, Corcept Therapeutics reported that full-year 2025 net income fell to US$99.65 million from US$141.21 million a year earlier, while guiding 202...
Corcept Therapeutics (CORT) is back in focus after disclosing a Complete Response Letter from the FDA for relacorilant in Cushing’s syndrome, followed by multip...
Corcept Therapeutics ((CORT)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level...
Analyst ratings
71%
of 7 ratingsMore CORT News
H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Corcept Therapeutics (CORT) to $60 from $67 and keeps a Buy rating on the shar...
Multiple shareholder class action lawsuits have been filed against Corcept Therapeutics (NasdaqCM:CORT) after the company disclosed that the FDA issued a Comple...
Reports Q4 revenue $202.1M, consensus $254.94M. “In 2025, our Cushing’s syndrome business experienced a surge in demand due to growing recognition among physici...
Corcept Therapeutics ( (CORT) ) has provided an update. On February 24, 2026, Corcept Therapeutics reported audited fourth-quarter and full-year 2025 results,...
If you are wondering whether Corcept Therapeutics at around US$34.82 is starting to look interesting on price, you are not alone. The stock has been drawing att...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.